MDGL vs VKTX
MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. VKTX: A clinical-stage biopharmaceutical company developing next-generation dual GLP-1/GIP receptor agonists for the treatment of obesity and metabolic disorders.
Side-by-side fundamentals
| Metric | MDGL | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $457.96 | $26.38 | |
| Market cap | $10.6B | $3.1B | |
| Net margin FY2025, SEC XBRL | -30.1% | n/a | |
| Operating margin FY2025, SEC XBRL | -31.3% | n/a | |
| ROE FY2025, SEC XBRL | -47.8% | -56.3% | MDGL higher |
| ROA FY2025, SEC XBRL | -22.9% | -50.2% | MDGL higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.65 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +432.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.64 | 1.50 | |
| 1-year return as of 2026-10-21 close | +6.5% | -20.0% | MDGL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.